Home Healthcare Pharmaceuticals Byler Disease Market

Byler Disease Market Size, Share & Trends Analysis Report By Disease Type (PFIC1, PFIC2, PFIC3, Atypical PFIC), By Treatment Type (IBAT Inhibitors, Antipruritics, Rifampicin, Bile-acid Sequestrants, Nutritional/Supportive Therapy), By Distribution Channel (Hospital pharmacy;, Drug Stores & Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 12, 2026 | Author: Straits Research Team | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Byler Disease Market, By Disease Type 2025-2034 (USD MILLION/ Units)
    1. PFIC1
    2. PFIC2
    3. PFIC3
    4. Atypical PFIC
  2. Byler Disease Market, By Treatment Type 2025-2034 (USD MILLION/ Units)
    1. IBAT Inhibitors
    2. Antipruritics
    3. Rifampicin
    4. Bile-acid Sequestrants
    5. Nutritional/Supportive Therapy
  3. Byler Disease Market, By Distribution Channel 2025-2034 (USD MILLION/ Units)
    1. Hospital pharmacy;
    2. Drug Stores & Retail Pharmacy
    3. Online Pharmacy
  4. Regional Byler Disease Market
    1. North America
      1. North America Byler Disease Market By Disease Type 2025-2034 (USD MILLION/ Units)
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
      2. North America Byler Disease Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. IBAT Inhibitors
        2. Antipruritics
        3. Rifampicin
        4. Bile-acid Sequestrants
        5. Nutritional/Supportive Therapy
      3. North America Byler Disease Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital pharmacy;
        2. Drug Stores & Retail Pharmacy
        3. Online Pharmacy
      4. U.S.
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      5. Canada
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
    2. Europe
      1. Europe Byler Disease Market By Disease Type 2025-2034 (USD MILLION/ Units)
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
      2. Europe Byler Disease Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. IBAT Inhibitors
        2. Antipruritics
        3. Rifampicin
        4. Bile-acid Sequestrants
        5. Nutritional/Supportive Therapy
      3. Europe Byler Disease Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital pharmacy;
        2. Drug Stores & Retail Pharmacy
        3. Online Pharmacy
      4. U.K.
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      5. Germany
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      6. France
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      7. Spain
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      8. Italy
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      9. Russia
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      10. Nordic
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      11. Benelux
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      12. Rest of Europe
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
    3. APAC
      1. APAC Byler Disease Market By Disease Type 2025-2034 (USD MILLION/ Units)
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
      2. APAC Byler Disease Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. IBAT Inhibitors
        2. Antipruritics
        3. Rifampicin
        4. Bile-acid Sequestrants
        5. Nutritional/Supportive Therapy
      3. APAC Byler Disease Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital pharmacy;
        2. Drug Stores & Retail Pharmacy
        3. Online Pharmacy
      4. China
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      5. Korea
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      6. Japan
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      7. India
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      8. Australia
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      9. Taiwan
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      10. South East Asia
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      11. Rest of Asia-Pacific
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
    4. Middle East and Africa
      1. Middle East and Africa Byler Disease Market By Disease Type 2025-2034 (USD MILLION/ Units)
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
      2. Middle East and Africa Byler Disease Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. IBAT Inhibitors
        2. Antipruritics
        3. Rifampicin
        4. Bile-acid Sequestrants
        5. Nutritional/Supportive Therapy
      3. Middle East and Africa Byler Disease Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital pharmacy;
        2. Drug Stores & Retail Pharmacy
        3. Online Pharmacy
      4. UAE
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      5. Turkey
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      6. Saudi Arabia
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      7. South Africa
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      8. Egypt
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      9. Nigeria
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      10. Rest of MEA
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
    5. LATAM
      1. LATAM Byler Disease Market By Disease Type 2025-2034 (USD MILLION/ Units)
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
      2. LATAM Byler Disease Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. IBAT Inhibitors
        2. Antipruritics
        3. Rifampicin
        4. Bile-acid Sequestrants
        5. Nutritional/Supportive Therapy
      3. LATAM Byler Disease Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital pharmacy;
        2. Drug Stores & Retail Pharmacy
        3. Online Pharmacy
      4. Brazil
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      5. Mexico
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      6. Argentina
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      7. Chile
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      8. Colombia
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
      9. Rest of LATAM
        1. PFIC1
        2. PFIC2
        3. PFIC3
        4. Atypical PFIC
        5. IBAT Inhibitors
        6. Antipruritics
        7. Rifampicin
        8. Bile-acid Sequestrants
        9. Nutritional/Supportive Therapy
        10. Hospital pharmacy;
        11. Drug Stores & Retail Pharmacy
        12. Online Pharmacy
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.